Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells

2 Feb 2022

Abstract excerpt

BACKGROUND: Endothelial cells (ECs) derived from human-induced pluripotent stem cell (iPSC) are a valuable cell resource for cardiovascular regeneration. To avoid time-consuming preparation from primary autologous cells, the allogeneic iPSC-ECs are being expected to become "off-the-shelf" cell products. However, allorejection caused by HLA mismatching is a major barrier for this strategy. Although the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Congenital heart defects research
Share to Mesenchymal stem cell research
Share to Pluripotent Stem Cells Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35109922
DOI: 10.1186/s13287-022-02720-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cellsPMID 35109922Read ↗

Genome editing HLA alleles for a pilot immunocompatible hESC line in a Chinese hESC bank for cell therapies.Semantic proximity Read ↗

Current status and future perspectives of HLA-edited induced pluripotent stem cellsSemantic proximity Read ↗

Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical applicationSemantic proximity Read ↗

Derivation of induced pluripotent stem cells line (RCPCMi007-A-1) with inactivation of the beta-2-microglobulin gene by CRISPR/Cas9 genome editingSemantic proximity Read ↗

Human Leukocyte Antigen Class I and II Knockout Human Induced Pluripotent Stem Cell–Derived Cells: Universal Donor for Cell TherapySemantic proximity Read ↗

iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell ImmunitySemantic proximity Read ↗

Generation of hypoimmunogenic universal iPSCs through HLA-type gene knockoutSemantic proximity Read ↗

Beneath the radar: immune-evasive cell sources for stroke therapySemantic proximity Read ↗

Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune CompatibilitySemantic proximity Read ↗

Development of immunocompatible pluripotent stem cells via CRISPR-based human leukocyte antigen engineeringSemantic proximity Read ↗

HLA‐E high /HLA‐G high /HLA‐II low Human iPSC‐Derived Cardiomyocytes Exhibit Low Immunogenicity for Heart RegenerationSemantic proximity Read ↗

Progenitor-derived human endothelial cells evade alloimmunity by CRISPR/Cas9-mediated complete ablation of MHC expressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.